

Aura Biosciences released early Phase 1 trial data on bel-sar for non-muscle-invasive bladder cancer, showing promising clinical activity and a favorable safety...
You can purchase shares of Aura Biosciences (NASDAQ:AURA) through any online brokerage.
Other companies in Aura Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Aura Biosciences has a consensus price target of $20.80.
The stock price for Aura Biosciences (NASDAQ: AURA) is $7.25 last updated November 9, 2026 at 11:04 AM EST.
There are no upcoming dividends for Aura Biosciences.
Aura Biosciences does not have any upcoming earnings scheduled.
There is no upcoming split for Aura Biosciences.
Aura Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical...